Today, He Gang, President of Huawei’s Consumer Business Smartphone Product Line, announced on Weibo that Huawei’s first smartwatch with blood pressure measurement capability has passed medical device registration testing. The next step will be to start registered clinical trials with professional medical institutions, and it is expected to be officially launched in the second half of the year.
Huawei announced three new health studies at the Huawei Fan Meeting in January, including hypertension management research, smart body temperature health research, and coronary heart disease screening research. Related research may be launched in 2021 based on Huawei’s wearable products.
He Gang said at the Huawei Fan Meeting:
Huawei is developing wearable blood pressure measurement equipment and will start research on hypertension management with well-known institutions to explore innovative active health management of blood pressure from screening to early intervention.
Huawei has also made breakthroughs in continuous body temperature monitoring technology based on smart wearables and is conducting joint research on intelligent body temperature to enable the screening of abnormal temperatures.
Huawei is conducting joint research on intelligent screening and early warning of coronary heart disease. With Huawei’s smartwatch ECG collection capabilities, it integrates PPG and ACC data to enable intelligent screening and early warning of coronary heart disease, helping consumers proactively manage their health.
In 2020, Huawei released the Watch GT 2 Pro ECG smartwatch, which is Huawei’s first smart wearable medical device to receive a Class II medical device registration certificate issued by the National Medical Products Administration of China.